Opendata, web and dolomites

AcTaferon

Revitalizing the clinical potential of type I IFNs in fighting influenza A virus infections with AcTaferon.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AcTaferon project word cloud

Explore the words cloud of the AcTaferon project. It provides you a very rough idea of what is the project "AcTaferon" about.

receptor    causing    concentration    underscore    efficient    extend    recognizes    site    drugs    actaferons    tackle    fundamental    company    inactive    serious    co    therapeutic    threat    fusing    too    eacute    viral    occasional    severe    limited    health    effect    cytokine    offers    cellular    saelens    tumor    ing    prof    marker    clinical    negatively    innovative    receptors    antiviral    drug    antitumor    en    substantial    sensitivity    doses    cells    actaferon    combining    huge    based    affinity    interdisciplinary    cancer    circumvents    body    mortality    route    transferred    epidemics    preliminary    pandemics    expertise    industrial    background    ifns    hence    regression    opportunity    academic    diseases    remained    obstacles    binding    intracellular    asset    regulate    activated    models    seasonal    ifn    surface    limits    broaden    miracle    influenza    pipeline    uz    vivo    morbidity    influence    administrable    pilot    infection    vitro    viruses    biological    interferons    fight    interferon    desired    moiety    orionis    mutant    respectively    strategy    unveils   

Project "AcTaferon" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.cordis.europa.eu/project/rcn/209395_en.html
 Total cost 144˙230 €
 EC max contribution 144˙230 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 144˙230.00

Map

 Project objective

Based on their antiviral and antitumor effect, type I interferons (IFNs) were believed to be the miracle drug to tackle viruses and cancer. However, clinical IFN applications remained limited due to severe side effects resulting from widespread cellular sensitivity to IFN, which limits the administrable doses. Hence, the drug concentration at the desired infection or tumor site is often too low to be fully therapeutic efficient. AcTaferon (Activated-by-Targeting interferon), co-developed by Prof. Uzé, circumvents these obstacles. By fusing an IFN mutant with strongly reduced receptor binding affinity to a targeting moiety that recognizes a surface marker on specific cells, AcTaferon remains inactive “en route” through the body and unveils its biological activity only on specific target cells. Robust tumor regression without side effects and preliminary antiviral effects underscore the huge clinical potential of AcTaferon to fight cancer and viral diseases. By combining the AcTaferon and influenza expertise of Prof. Uzé and Prof. Saelens, respectively, this interdisciplinary project offers the opportunity to broaden the innovative AcTaferon therapeutic strategy from the cancer to the viral infection field. Influenza A was selected as a pilot target as seasonal influenza A epidemics and occasional pandemics remain a serious health threat causing substantial morbidity and mortality. Influenza A-targeted AcTaferons will be developed and analyzed in relevant in vitro and in vivo models. Eventually, all knowledge will be transferred to Orionis, a company that will implement the AcTaferon technology to develop novel drugs. My background on the intracellular processes that negatively regulate cytokine receptors and hence influence the cellular sensitivity to a (therapeutic) cytokine is an asset to this project. I will be able to extend my fundamental research experience with applied cytokine research, which may extend into a new academic or industrial research pipeline.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACTAFERON" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ACTAFERON" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More